AI assistant
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2025
Feb 19, 2025
31542_dirs_2025-02-19_a2719182-73e0-4fe8-a94a-a5a27c19dbce.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2025-02-14
Reporting Person: Sundaram Preethi (Chief Strategy Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-14 | Common Stock, par value $0.001 per share | M | 16667 | — | Acquired | 50970 | Direct |
| 2025-02-14 | Common Stock, par value $0.001 per share | F | 5965 | — | Disposed | 45005 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-14 | Restricted Stock Units | $ | M | 16667 | Disposed | Common Stock (16667) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units.
F3: Derivative securities vested in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025.
F4: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The final tranche of shares was delivered on February 14, 2025.